In December of 2013, two co-founders residing in CT joined together, establishing Tangen Biosciences, each bringing extensive industry experience developing and commercializing gene synthesis platform and next-generation sequencing technologies.
When founding Tangen, their goal was to get high-quality molecular diagnostics for infectious diseases out of the laboratory and closer to the patient, including remote, rural, and underserved communities. They developed the initial instrument prototype in the basement of one of the co-founders’ homes in Guilford, Connecticut. The company has experienced fast growth in the last several years and has grown to over 50 employees today in a 16,000 square foot office, lab, and clean room manufacturing facility.
Richard Birkmeyer was appointed as
Tangen’s President and CEO
BARDA awarded a contract to Tangen to detect Anthrax directly from blood
Completed $2MM Seed Round equity financing
Developing GeneSpark – A portable, rapid and easy-to-use molecular diagnostic platform
The Company was founded